Results 1 to 10 of about 21,053 (285)

Efficacy and Safety of Low‐Dose Edoxaban by Body Weight in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the Randomized ELDERCARE‐AF Trial

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease
Background The ELDERCARE‐AF trial showed that low‐dose edoxaban benefits elderly patients with nonvalvular atrial fibrillation considered ineligible for standard oral anticoagulants due to high bleeding risk, but whether this applied to patients with ...
M. Akao, T. Yamashita, Masayuki Fukuzawa, Takuya Hayashi, K. Okumura   +4 more
semanticscholar   +1 more source

Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial

JAMA Network Open, 2022
Key Points Question Is very-low-dose edoxaban (15 mg/day) beneficial across frailty status among very elderly Japanese patients with atrial fibrillation considered ineligible for standard dose oral anticoagulants because of their high bleeding risk ...
Shintaro Akashi, M. Oguri, E. Ikeno, M. Manita, Junki Taura, Saori Watanabe, Takuya Hayashi, M. Akao, K. Okumura, M. Akishita, T. Yamashita   +10 more
semanticscholar   +1 more source

Clinical outcomes in patients receiving edoxaban or phenprocoumon for prevention of stroke in atrial fibrillation: a German real-world cohort study

Thrombosis Journal, 2022
Background Appropriate and timely anticoagulant therapy with vitamin K antagonists (VKAs) or non-vitamin K oral antagonists (NOACs) is essential for stroke prevention in non-valvular atrial fibrillation (NVAF).
Christopher Hohmann, Magnus Lutz, Sheila Vignali, Kathrin Borchert, Karolin Seidel, Sebastian Braun, Stephan Baldus, Michael Näbauer   +7 more
doaj   +1 more source

More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. [PDF]

, 2018
© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the ...
Farag M, Hirsh J, Ibanez B, Mega JL, Park KW, Suh JW, Valgimigli M   +6 more
core   +3 more sources

Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban

Thrombosis and Haemostasis, 2022
Background Andexanet alfa (andexanet) is approved for specific anticoagulation reversal in patients with life-threatening or uncontrolled bleeding during treatment with rivaroxaban or apixaban.
A. Benz, Lizhen Xu, J. Eikelboom, S. Middeldorp, T. Milling, M. Crowther, Patrick Yue, P. Conley, Genmin Lu, S. Connolly   +9 more
semanticscholar   +1 more source

Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban‐treated patients and healthy controls

Research and Practice in Thrombosis and Haemostasis, 2022
Introduction The activated partial thromboplastin time (aPTT) and the prothrombin time (PT) are widely available coagulation parameters which are however poor predictors of the anticoagulant effect of direct oral anticoagulants (DOACs).
Jonathan Evrard, Romain Siriez, Céline Bouvy, Julien Favresse, Halil Yildiz, Philippe Hainaut, François Mullier, Jean‐Michel Dogné, Jonathan Douxfils   +8 more
doaj   +1 more source

Clinical considerations on the posology of direct oral anticoagulants [PDF]

, 2016
Los anticoagulantes dicumarínicos han demostrado su eficacia en pacientes con fibrilación auricular no valvular. Sin embargo, presentan desventajas como la necesidad de ajustar la dosis y la interacción con fármacos y alimentos.
Avendaño Solá, C., González Juanatey, J.R., Peñataro Sáez, J.   +2 more
core   +2 more sources

Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care

European Heart Journal - Cardiovascular Pharmacotherapy, 2022
Aims Patients with atrial fibrillation (AF) treated with oral anticoagulation still suffer from cardiovascular complications including cardiovascular death, stroke, and major bleeding.
P. Kirchhof, L. Pecen, A. Bakhai, C. de Asmundis, J. D. de Groot, J. Deharo, P. Kelly, P. Levy, E. Lopez-de-Sa, P. Monteiro, J. Steffel, J. Waltenberger, T. Weiss, P. Laeis, M. Manu, José Souza, R. de Caterina   +16 more
semanticscholar   +1 more source

The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease

Research and Practice in Thrombosis and Haemostasis, 2020
Background Little evidence is available for treatment of pediatric venous thromboembolism (VTE). Large randomized controlled trials are challenging in children.
Cornelia Heleen vanOmmen, Manuela Albisetti, Anthony K. Chan, Jeremie Estepp, Julie Jaffray, Gili Kenet, Guy Young, Jay Dave, Michael A. Grosso, Anil Duggal   +9 more
doaj   +1 more source

Pharmacokinetics of anticoagulant edoxaban in overdose in a Japanese patient transported to hospital

Journal of Pharmaceutical Health Care and Sciences, 2020
Background The anticoagulant edoxaban is used clinically at doses of 30–60 mg/day; however, we experienced a patient who had taken an overdose of edoxaban of 750 mg.
Koichiro Adachi, Jumpei Tuchiya, Satoru Beppu, Kei Nishiyama, Makiko Shimizu, Hiroshi Yamazaki   +5 more
doaj   +1 more source